A Study of LY3361237 in Participants With Psoriasis

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis

The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis. LY3361237 will be administered by injections just under the skin. The study will last up to 41 weeks and may include up to 15 visits to the study center.

Inclusion Criteria:

• Have chronic plaque psoriasis for at least 6 months
• Be willing and able to undergo skin biopsies
• Body mass index (BMI) within the range of 18 to 40 kilograms per meter squared (kg/m²)
• Female participants must agree to use birth control during the study

Exclusion Criteria:

• Have had certain types of infection within the last six months
• Have a clinically significant active infection, or recent acute active infection within the last 30 days
• Have other serious or unstable illnesses
• Have a history of organ or bone marrow transplant
• Have received any live vaccine within the last 4 weeks prior to screening
• Have received systemic nonbiologic psoriasis therapy within 4 weeks prior to study day 1
• Have received topical psoriasis treatment within 14 days prior to study day 1
• Have excessive skin exposure or use tanning booths for at least 4 weeks prior to study day 1